145 related articles for article (PubMed ID: 38773967)
1. AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia.
Vandewalle N; Satilmis H; Verheye E; Fan R; Wang Y; De Groof TWM; Bridoux J; Kerre T; De Beule N; De Becker A; De Bruyne E; Menu E; Vanderkerken K; Breckpot K; Devoogdt N; De Veirman K
Theranostics; 2024; 14(7):2656-2674. PubMed ID: 38773967
[No Abstract] [Full Text] [Related]
2. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma.
Ben-Batalla I; Schultze A; Wroblewski M; Erdmann R; Heuser M; Waizenegger JS; Riecken K; Binder M; Schewe D; Sawall S; Witzke V; Cubas-Cordova M; Janning M; Wellbrock J; Fehse B; Hagel C; Krauter J; Ganser A; Lorens JB; Fiedler W; Carmeliet P; Pantel K; Bokemeyer C; Loges S
Blood; 2013 Oct; 122(14):2443-52. PubMed ID: 23982172
[TBL] [Abstract][Full Text] [Related]
3. Antibody-mediated neutralization of autocrine Gas6 inhibits the growth of pancreatic ductal adenocarcinoma tumors in vivo.
Moody G; Belmontes B; Masterman S; Wang W; King C; Murawsky C; Tsuruda T; Liu S; Radinsky R; Beltran PJ
Int J Cancer; 2016 Sep; 139(6):1340-9. PubMed ID: 27170265
[TBL] [Abstract][Full Text] [Related]
4. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S
Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360
[TBL] [Abstract][Full Text] [Related]
5. Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia.
Niu X; Rothe K; Chen M; Grasedieck S; Li R; Nam SE; Zhang X; Novakovskiy GE; Ahn YH; Maksakova I; Lai S; Zhang H; Yan J; Liu H; Zhao Y; Wu D; Ge Y; Wasserman WW; Rouhi A; Kuchenbauer F; Yip CK; Zhang Z; Jiang X
Blood; 2021 Jul; 137(26):3641-3655. PubMed ID: 33786587
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.
Park IK; Mishra A; Chandler J; Whitman SP; Marcucci G; Caligiuri MA
Blood; 2013 Mar; 121(11):2064-73. PubMed ID: 23321254
[TBL] [Abstract][Full Text] [Related]
7. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.
Leconet W; Larbouret C; Chardès T; Thomas G; Neiveyans M; Busson M; Jarlier M; Radosevic-Robin N; Pugnière M; Bernex F; Penault-Llorca F; Pasquet JM; Pèlegrin A; Robert B
Oncogene; 2014 Nov; 33(47):5405-14. PubMed ID: 24240689
[TBL] [Abstract][Full Text] [Related]
8. Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?
Janning M; Ben-Batalla I; Loges S
Expert Rev Hematol; 2015 Apr; 8(2):135-8. PubMed ID: 25578023
[TBL] [Abstract][Full Text] [Related]
9. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.
Park IK; Mundy-Bosse B; Whitman SP; Zhang X; Warner SL; Bearss DJ; Blum W; Marcucci G; Caligiuri MA
Leukemia; 2015 Dec; 29(12):2382-9. PubMed ID: 26172401
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.
Leconet W; Chentouf M; du Manoir S; Chevalier C; Sirvent A; Aït-Arsa I; Busson M; Jarlier M; Radosevic-Robin N; Theillet C; Chalbos D; Pasquet JM; Pèlegrin A; Larbouret C; Robert B
Clin Cancer Res; 2017 Jun; 23(11):2806-2816. PubMed ID: 27923843
[No Abstract] [Full Text] [Related]
11. Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies.
Kariolis MS; Miao YR; Diep A; Nash SE; Olcina MM; Jiang D; Jones DS; Kapur S; Mathews II; Koong AC; Rankin EB; Cochran JR; Giaccia AJ
J Clin Invest; 2017 Jan; 127(1):183-198. PubMed ID: 27893463
[TBL] [Abstract][Full Text] [Related]
12. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J
Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423
[TBL] [Abstract][Full Text] [Related]
13. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
[TBL] [Abstract][Full Text] [Related]
14. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance.
Xiong R; Sun XX; Wu HR; Xu GW; Wang GX; Sun XH; Xu MQ; Xie MR
Thorac Cancer; 2020 Jan; 11(1):156-165. PubMed ID: 31777195
[TBL] [Abstract][Full Text] [Related]
15. Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma.
Liu R; Gong M; Li X; Zhou Y; Gao W; Tulpule A; Chaudhary PM; Jung J; Gill PS
Blood; 2010 Jul; 116(2):297-305. PubMed ID: 20442363
[TBL] [Abstract][Full Text] [Related]
16. Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.
von Mässenhausen A; Brägelmann J; Billig H; Thewes B; Queisser A; Vogel W; Kristiansen G; Schröck A; Bootz F; Brossart P; Kirfel J; Perner S
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025482
[TBL] [Abstract][Full Text] [Related]
17. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
[TBL] [Abstract][Full Text] [Related]
18. Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy.
Badarni M; Prasad M; Balaban N; Zorea J; Yegodayev KM; Joshua BZ; Dinur AB; Grénman R; Rotblat B; Cohen L; Elkabets M
JCI Insight; 2019 Mar; 5(8):. PubMed ID: 30860495
[TBL] [Abstract][Full Text] [Related]
19. Development of the phenylpyrazolo[3,4-
Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
[No Abstract] [Full Text] [Related]
20. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P
Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
